Background: Resistin (RSN) is an adipocytokine involved in insulin
resistance, obesity and atherosclerosis. This study aimed to investigate
the association between plasma RSN and outcome after ischemic stroke.
Methods: RSN measured within 24 h after the event was related to
functional outcome and 5-year survival in 211 subjects with first-ever
atherothrombotic ischemic stroke. Prognosis was assessed by the Kaplan
Meier and the Cox techniques.
Results: The probabilities of death were 80.4%, 46.2% and 15.7% (p <
0.001) for patients stratified according to tertiles of RSN (> 30 ng/mL,
2030 ng/mL and < 20 ng/mL, respectively). The proportion of dependency
(modified Rankin Scale score ! 3) was greater in 5-year survivors with
RSN in the upper tertile (6/11 [54.5%]) compared to the middle (20/56
[35.7%]) and the lowest tertile (8/43 [18.6%]; p < 0.01).
C-reactive protein levels (hazard ratio [HR] 3.96 [95% CI 2.06,
8.91]; p < 0.001), coronary heart disease (2.69 [1.62, 6.23]; p <
0.001), RSN levels (2.12 [1.31, 5.08] p < 0.001), National Institute
of Health Stroke Scale score (2.02 [1.23, 4.49]; p < 0.01) and age
(1.84 [1.19, 3.93]; p < 0.01) were independent predictors of death.
Conclusions: High plasma RSN appears to be associated with increased
risk of 5-year mortality or disability after atherothrombotic ischemic
stroke, independently of other adverse predictors. (c) 2006 Elsevier
B.V. All rights reserved